Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 99.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,080 shares of the biopharmaceutical company’s stock after purchasing an additional 22,473 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Alnylam Pharmaceuticals were worth $8,629,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Quent Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares during the period. KB Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at approximately $35,000. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $38,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Alnylam Pharmaceuticals by 59.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 373 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 139 shares during the period. Finally, First Capital Advisors Group LLC. acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $80,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ALNY. Chardan Capital reduced their price target on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Citigroup reduced their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research report on Friday, February 16th. HC Wainwright reissued a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Royal Bank of Canada reissued an “outperform” rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. Nine investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $144.41 on Friday. The stock has a market capitalization of $18.19 billion, a P/E ratio of -40.56 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $143.50 and a one year high of $218.88. The company has a 50 day moving average price of $151.56 and a two-hundred day moving average price of $166.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the business earned ($1.68) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.